Press Releases May 11, 2026 04:05 PM

Outset Medical to Present at RBC Global Healthcare Conference

Outset Medical to Present at RBC Global Healthcare Conference, Highlighting Innovative Dialysis Technology

By Avery Klein OM

Outset Medical announced that its management will present at the RBC Capital Markets Global Healthcare conference to discuss its pioneering Tablo Hemodialysis System, which improves clinical outcomes while reducing cost and complexity in dialysis treatment. The FDA-cleared system is widely adopted in U.S. healthcare facilities and integrates advanced technology for dialysis management.

Outset Medical to Present at RBC Global Healthcare Conference
OM

Key Points

  • Outset Medical will present at a major healthcare investment conference, increasing visibility among investors.
  • The company's Tablo Hemodialysis System is FDA-cleared and adopted by over 1,000 U.S. healthcare facilities, supporting millions of treatments.
  • Tablo integrates water purification, dialysate production, EMR connectivity, and data analytics, aiming to improve clinical, operational, and financial outcomes in kidney care.

SAN JOSE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced that members of management will participate at the RBC Capital Markets Global Health Care conference on Tuesday, May 19, 2026, at 10:30 a.m. Eastern time.

The live and archived webcast of the session will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.

About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.

Contact
[email protected]


Risks

  • Market adoption and continued acceptance of Tablo in a competitive dialysis device market.
  • Regulatory risks regarding maintaining FDA clearance and any potential future regulatory changes impacting medical devices.
  • Dependence on U.S. healthcare providers’ budgets and reimbursement policies affecting adoption rates.

More from Press Releases

Banzai to Host First Quarter 2026 Financial Results Conference Call on Friday, May 15, 2026 at 4:30 p.m. Eastern Time May 12, 2026 Agora, Inc. to Report First Quarter 2026 Financial Results on May 26, 2026 May 12, 2026 Auburn National Bancorporation, Inc. Declares Quarterly Dividend May 12, 2026 Highwoods Sells Bridgestone Tower in CBD Nashville May 12, 2026 Algoma Steel Group Inc. Reports Financial Results for the Three Months Ended March 31, 2026 May 12, 2026